prednisone has been researched along with Coronary Restenosis in 13 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The "expected" secondary effects of the steroid treatment are described, together with the "unexpected" occurrence of likely drug-induced neutropenia observed in patients prescribed prednisone and thienopyridines simultaneously after PCI." | 7.74 | Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions. ( Brunelleschi, S; Feola, M; Ferrero, V; Ribichini, F; Rognoni, A; Vacca, G; Vassanelli, C, 2007) |
| "Out of 40 patients with coronary artery disease treated with BMS implantation, 20 were randomly assigned to receive oral prednisone during 40 days according to a standardized protocol." | 5.14 | Cytokines release inhibition from activated monocytes, and reduction of in-stent neointimal growth in humans. ( Amoruso, A; Bardelli, C; Brunelleschi, S; De Luca, G; Ferrero, V; Fresu, LG; Perobelli, L; Pesarini, G; Ribichini, F; Scappini, P; Vassanelli, C, 2010) |
| " The "expected" secondary effects of the steroid treatment are described, together with the "unexpected" occurrence of likely drug-induced neutropenia observed in patients prescribed prednisone and thienopyridines simultaneously after PCI." | 3.74 | Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions. ( Brunelleschi, S; Feola, M; Ferrero, V; Ribichini, F; Rognoni, A; Vacca, G; Vassanelli, C, 2007) |
| "Prednisone-treated patients did not develop new treatment-related clinical problems." | 2.78 | Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Re ( Boccuzzi, G; De Luca, G; Ferrero, V; Ghini, AS; Marino, P; Pesarini, G; Presbitero, P; Ribichini, F; Rognoni, A; Tomai, F; Vassanelli, C; Zivelonghi, C, 2013) |
| "Aim of the study was to assess the clinical and angiographic efficacy of oral treatment with prednisone at immunosuppressive dosage after percutaneous coronary interventions (PCI) in patients with bifurcation lesions treated with elective bare metal stent (BMS) implantation in the main-branch (MB) and provisional stenting in the side-branch (SB)." | 2.73 | Percutaneous treatment of coronary bifurcations: lesion preparation before provisional bare metal stenting and subsequent immunosuppression with oral prednisone. The IMPRESS-Y study. ( Brunelleschi, S; Ferrero, V; Marino, P; Ribichini, F; Rognoni, A; Vassanelli, C, 2007) |
| "This study assessed clinical and angiographic efficacies of oral treatment with prednisone at low-dose (LD) versus the previous high-dose (HD) immunosuppressive dosage used after percutaneous coronary interventions (PCIs) with bare metal stents in patients with multivessel coronary artery disease." | 1.34 | Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study). ( Brunelleschi, S; Ferrero, V; Marino, P; Ribichini, F; Rognoni, A; Vassanelli, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ribichini, F | 9 |
| Tomai, F | 5 |
| Pesarini, G | 4 |
| Zivelonghi, C | 1 |
| Rognoni, A | 4 |
| De Luca, G | 5 |
| Boccuzzi, G | 3 |
| Presbitero, P | 3 |
| Ferrero, V | 8 |
| Ghini, AS | 4 |
| Marino, P | 5 |
| Vassanelli, C | 8 |
| Waksman, R | 1 |
| Epstein, SE | 1 |
| Cassese, S | 1 |
| Cernigliaro, C | 1 |
| Sansa, M | 1 |
| Versaci, F | 2 |
| Proietti, I | 2 |
| Stankovic, G | 1 |
| Stojkovic, S | 1 |
| Fernandez-Pereira, C | 1 |
| Antoniucci, D | 1 |
| Serruys, PW | 1 |
| Kastrati, A | 1 |
| Rodriguez, AE | 1 |
| Pastori, F | 1 |
| De Luca, L | 2 |
| Zavalloni, D | 2 |
| Soregaroli, D | 2 |
| Garbo, R | 2 |
| Franchi, E | 1 |
| Minelli, M | 1 |
| Amoruso, A | 1 |
| Bardelli, C | 1 |
| Fresu, LG | 1 |
| Perobelli, L | 1 |
| Scappini, P | 1 |
| Brunelleschi, S | 4 |
| Abukaresh, R | 1 |
| Aurigemma, C | 1 |
| Zanolla, L | 1 |
| Chatterjee, S | 2 |
| Sardar, P | 1 |
| Mukherjee, D | 1 |
| Garratt, KN | 1 |
| Gaspardone, A | 1 |
| Russo, P | 1 |
| Chiariello, L | 1 |
| Gioffrè, PA | 1 |
| Romeo, F | 1 |
| Crea, F | 1 |
| Arruda, JA | 1 |
| Costa, MA | 1 |
| Brito, FS | 1 |
| Tedesco, H | 1 |
| Barbosa, AH | 1 |
| Ribeiro, EP | 1 |
| Pestana, JO | 1 |
| Lima, VC | 1 |
| Feola, M | 1 |
| Vacca, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical and Angiographic Outcome of Patients Treated With Bare Metal Stent (BMS) Implantation Compared With Drug Eluting Stents or BMS Plus Systemic Prednisone Therapy. A Randomized, Multicentre Study.[NCT00369356] | Phase 2/Phase 3 | 375 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Erythrocyte-Mediated Drug Delivery for the Prevention of Restenosis After Coronary Artery Stent Implantation:TROY-Study[NCT00484965] | Phase 4 | 100 participants (Anticipated) | Interventional | 2007-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for prednisone and Coronary Restenosis
| Article | Year |
|---|---|
ORAl iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: a patient-level meta-analysis of randomized trials.
Topics: Administration, Oral; Aged; Coronary Restenosis; Drug-Eluting Stents; Female; Follow-Up Studies; Hum | 2014 |
Steroids for the prevention of restenosis in bare-metal stents--a systematic review and meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Coronary Stenosis; Humans; Metals; Outcome Asse | 2012 |
7 trials available for prednisone and Coronary Restenosis
| Article | Year |
|---|---|
Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Re
Topics: Administration, Oral; Anti-Inflammatory Agents; Coronary Restenosis; Cortisone; Drug Therapy, Combin | 2013 |
A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study desig
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Coronary Restenosis; Coronary Stenosis; Cortis | 2009 |
Cytokines release inhibition from activated monocytes, and reduction of in-stent neointimal growth in humans.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Coronary Restenosis; Cytokines; Femal | 2010 |
Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI. A multicenter randomized trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Coronary Restenosis; Coronary Stenosis; | 2011 |
Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study).
Topics: Adult; Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; C-Reactive Protein; Coronary A | 2002 |
Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study).
Topics: Adult; Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; C-Reactive Protein; Coronary A | 2002 |
Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study).
Topics: Adult; Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; C-Reactive Protein; Coronary A | 2002 |
Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study).
Topics: Adult; Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; C-Reactive Protein; Coronary A | 2002 |
Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients.
Topics: Azathioprine; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Cyclosporine; Drug Therap | 2003 |
Percutaneous treatment of coronary bifurcations: lesion preparation before provisional bare metal stenting and subsequent immunosuppression with oral prednisone. The IMPRESS-Y study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anti-Inflammat | 2007 |
4 other studies available for prednisone and Coronary Restenosis
| Article | Year |
|---|---|
Prednisone: the last gasp of immunosuppresive therapy for restenosis prevention.
Topics: Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Immunosuppressive Agents; Male; Percutaneo | 2013 |
Regarding immunosuppressive therapy to prevent restenosis after PCI.
Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Coronary Stenosis; Female; Humans; Immunosuppre | 2012 |
Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study).
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Case-Control Studies | 2007 |
Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Infective Agents; Coronary Restenosis; Drug-Related Side | 2007 |